SCHEMBL849432

SCHEMBL849432

FC(F)(F)CCCCCBr

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9560069 1.00
SCHEMBL13265281 1.00
SCHEMBL11248962 1.00
SCHEMBL31077618 1.00
SCHEMBL31077556 1.00
SCHEMBL9260249 1.00
SCHEMBL9364968 1.00
SCHEMBL31077529 1.00
SCHEMBL593834 0.97
SCHEMBL10769685 0.94

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270173-A1 PYRIDINE DERIVATIVES FOR TREATING PSYCHIATRIC DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2025-08-28 US disclosed
EP-4562019-A1 IP5 SUBSTITUTED COMPOUNDS Sanifit Therapeutics S.A. (ES) 2025-06-04 EP disclosed
EP-4561585-A1 IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION Sanifit Therapeutics S.A. (ES) 2025-06-04 EP disclosed
WO-2025085701-A1 PYRIDINE DERIVATIVES FOR TREATING PSYCHIATRIC DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2025-04-24 WO disclosed
EP-4511029-A1 PYRIDINE DERIVATIVES FOR TREATING PSYCHIATRIC DISORDERS Gilgamesh Pharmaceuticals, Inc. (US) 2025-02-26 EP disclosed
US-20240400588-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA STEALTH BIOTHERAPEUTICS INC. (US) 2024-12-05 US disclosed
US-12037350-B2 Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia STEALTH BIOTHERAPEUTICS INC. (US) 2024-07-16 US disclosed
US-12037350-B2 Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia STEALTH BIOTHERAPEUTICS INC. (US) 2024-07-16 US disclosed
US-20240109924-A1 IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS VIFOR (INTERNATIONAL) LTD. (CH) 2024-04-04 US disclosed
WO-2024059017-A2 PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME GILGAMESH PHARMACEUTICALS, INC. (US) 2024-03-21 WO disclosed
US-5401851-A Preparation of proline derivatives ELI LILLY AND COMPANY (US) 1995-03-28 US disclosed
WO-1995005379-A1 ANTIPSYCHOTIC METHOD NOVO NORDISK A/S (DK) 1995-02-23 WO disclosed
WO-1994020496-A1 HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1994-09-15 WO disclosed
US-5310745-A Acylated derivatives of 1,5-dideoxy-1,5-imino-D-glucitol, AIDS G. D. SEARLE & CO. (US) 1994-05-10 US disclosed
CN-1085897-A Angiotension II antagonists LILLY CO ELI (US) 1994-04-27 CN disclosed
EP-0573271-A1 Angiotensin II antagonists ELI LILLY AND COMPANY (US) 1993-12-08 EP disclosed
US-5221746-A Inhibitors of visna virus; treatment of AIDS and ARC G. D. SEARLE & CO. (US) 1993-06-22 US disclosed
US-5144037-A Viricides G. D. SEARLE & CO. (US) 1992-09-01 US disclosed
EP-0494850-A2 Novel antiviral compounds G.D. Searle &amp; Co. (US) 1992-07-15 EP disclosed
EP-0459748-A2 Thien-2-yl methylurea derivatives as leukotriene inhibitors LILLY INDUSTRIES LIMITED (GB) 1991-12-04 EP disclosed